Works matching IS 01676997 AND DT 2024 AND VI 42 AND IP 3

Results: 12

Evolving or immutable - phase I solid tumor trials in the era of precision oncology.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 326, doi. 10.1007/s10637-024-01445-z

By:

Stockton, Shannon S.;
Ayers, G. Dan;
Lee, Cody;
Laferriere, Heather;
Das, Satya;
Berlin, Jordan

Publication type:

Article

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Published in:

2024

By:

Armstrong, Andrew J.;
Geva, Ravit;
Chung, Hyun Cheol;
Lemech, Charlotte;
Miller Jr, Wilson H.;
Hansen, Aaron R.;
Lee, Jong-Seok;
Tsai, Frank;
Solomon, Benjamin J.;
Kim, Tae Min;
Rolfo, Christian;
Giranda, Vincent;
Ren, Yixin;
Liu, Fang;
Kandala, Bhargava;
Freshwater, Tomoko;
Wang, Judy S.

Publication type:

Correction Notice

In vitro results with minimal blood toxicity of a combretastatin A4 analogue.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 318, doi. 10.1007/s10637-024-01440-4

By:

Chagas, Camila;
Mansano, Jaqueline Vital;
da Silva, Emerson Barbosa;
Petri, Giuliana;
da Costa Aguiar Alves Reis, Beatriz;
Schumacher, Maria Lúcia;
Haddad, Paula Silvia;
Pereira, Edimar Cristiano;
Britos, Tatiane Nassar;
Barreiro, Eliezer J.;
Lima, Lídia Moreira;
Ferreira, Fabio Furlan;
Fonseca, Fernando Luiz Affonso

Publication type:

Article

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 281, doi. 10.1007/s10637-024-01432-4

By:

Hori, Tomoki;
Yamamoto, Kazuhiro;
Ito, Takefumi;
Ikushima, Shigeki;
Omura, Tomohiro;
Yano, Ikuko

Publication type:

Article

Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 335, doi. 10.1007/s10637-024-01437-z

By:

Li, Wenjie;
Wang, Wei

Publication type:

Article

The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 289, doi. 10.1007/s10637-024-01436-0

By:

Cao, Bei;
Ma, Tingting;
Zhang, Yuqiang;
Huang, Lei;
Lin, Hui;
Jiang, Huanhuan;
Zhao, Yu;
Geng, Yan;
Yang, Yuanxun;
Cao, Sumin;
Li, Juan

Publication type:

Article

Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 299, doi. 10.1007/s10637-024-01435-1

By:

Zhou, Huifen;
Wu, Xiaoxia;
Yang, Zhen;
Lu, Shenqi;
Zhang, Xinhui;
Yang, Xiaofei;
Chen, Suning;
Wu, Depei;
Miao, Miao

Publication type:

Article

The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 272, doi. 10.1007/s10637-024-01434-2

By:

Safari, Fatemeh;
Bararpour, Setareh;
Omidi Chomachaei, Fatemeh

Publication type:

Article

The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 309, doi. 10.1007/s10637-024-01439-x

By:

Liu, Xinyi;
Guo, Zihan;
Su, Lin;
Zuo, Anli;
Gao, Min;
Ji, Xiang;
Lu, Jiameng;
Yang, Shuran;
Jiang, Yunxiu;
Lu, Degan

Publication type:

Article

Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 252, doi. 10.1007/s10637-024-01429-z

By:

Fujita, Kazuma;
Taguchi, Daiki;
Fukuda, Koji;
Yoshida, Taichi;
Shimazu, Kazuhiro;
Shinozaki, Hanae;
Shibata, Hiroyuki;
Miura, Masatomo

Publication type:

Article

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 241, doi. 10.1007/s10637-024-01428-0

By:

Chénard-Poirier, Maxime;
Hansen, Aaron R.;
Gutierrez, Martin E.;
Rasco, Drew;
Xing, Yan;
Chen, Lin-Chi;
Zhou, Heng;
Webber, Andrea L.;
Freshwater, Tomoko;
Sharma, Manish R.

Publication type:

Article

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 261, doi. 10.1007/s10637-024-01422-6

By:

Yamamoto, Noboru;
Satouchi, Miyako;
Doi, Toshihiko;
Fujiwara, Yutaka;
Yanagitani, Noriko;
Kawa, Yoshitaka;
Yoh, Kiyotaka;
Leopold, Lance;
Munteanu, Mihaela;
Sawada, Takashi;
Han, Shirong;
Noguchi, Kazuo;
Nishio, Makoto

Publication type:

Article